|
G |
Aadat |
aminoadipate aminotransferase |
decreases activity |
EXP |
Triiodothyronine results in decreased activity of AADAT protein |
CTD |
PMID:32663543 |
|
NCBI chr16:29,509,392...29,544,332
Ensembl chr16:29,509,394...29,544,332
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ABCA1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity multiple interactions increases expression |
ISO EXP |
Triiodothyronine results in decreased activity of ABCB11 protein [BMS201038 co-treated with Triiodothyronine] results in increased expression of ABCB11 mRNA Triiodothyronine results in increased expression of ABCB11 mRNA |
CTD |
PMID:28437613 PMID:34902352 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
Triiodothyronine results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ABCC5 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Abcf3 |
ATP binding cassette subfamily F member 3 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of ABCF3 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr11:80,340,476...80,352,211
Ensembl chr11:80,339,977...80,352,211
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression multiple interactions |
EXP |
Triiodothyronine results in increased expression of ABCG5 mRNA [BMS201038 co-treated with Triiodothyronine] results in increased expression of ABCG5 mRNA |
CTD |
PMID:34902352 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression multiple interactions |
EXP |
Triiodothyronine results in increased expression of ABCG8 mRNA [BMS201038 co-treated with Triiodothyronine] results in increased expression of ABCG8 mRNA |
CTD |
PMID:34902352 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions increases activity increases expression |
EXP ISO |
Triiodothyronine inhibits the reaction [Streptozocin results in decreased activity of ACACA protein]; Triiodothyronine inhibits the reaction [Streptozocin results in decreased expression of ACACA mRNA] Triiodothyronine results in increased activity of ACACA protein Triiodothyronine results in increased expression of ACACA mRNA [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA] |
CTD |
PMID:1973097 PMID:33476690 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acbd4 |
acyl-CoA binding domain containing 4 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of ACBD4 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr10:88,048,058...88,062,612
Ensembl chr10:88,048,108...88,058,500
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
EXP |
Triiodothyronine results in increased expression of and results in increased activity of ACE protein |
CTD |
PMID:1659346 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression decreases expression |
EXP |
Triiodothyronine results in increased expression of ACOT1 mRNA Triiodothyronine results in decreased expression of ACOT1 mRNA |
CTD |
PMID:15953391 PMID:28299817 |
|
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions increases expression |
EXP |
[BMS201038 co-treated with Triiodothyronine] results in increased expression of ACOX1 mRNA Triiodothyronine results in increased expression of ACOX1 mRNA |
CTD |
PMID:34902352 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ACSL1 mRNA |
CTD |
PMID:30209975 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Acsl5 |
acyl-CoA synthetase long-chain family member 5 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ACSL5 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607
|
|
G |
Acvrl1 |
activin A receptor like type 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ACVRL1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 7:132,239,200...132,256,592
Ensembl chr 7:132,239,729...132,256,591
|
|
G |
Adam11 |
ADAM metallopeptidase domain 11 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ADAM11 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr10:87,724,115...87,742,773
Ensembl chr10:87,724,234...87,741,562
|
|
G |
Adam12 |
ADAM metallopeptidase domain 12 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ADAM12 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 1:188,686,984...189,014,206
Ensembl chr 1:188,686,989...189,020,667
|
|
G |
Adam15 |
ADAM metallopeptidase domain 15 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of ADAM15 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 2:174,754,629...174,765,136
Ensembl chr 2:174,754,633...174,765,113
|
|
G |
Adam19 |
ADAM metallopeptidase domain 19 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of ADAM19 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr10:30,491,362...30,583,115
Ensembl chr10:30,491,405...30,583,105
|
|
G |
Add2 |
adducin 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ADD2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 4:118,444,594...118,538,505
Ensembl chr 4:118,497,416...118,538,505
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein] |
CTD |
PMID:33476690 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ADRB1 mRNA; Triiodothyronine results in increased expression of ADRB1 protein |
CTD |
PMID:10217540 PMID:11090638 |
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions increases expression |
ISO |
bicalutamide inhibits the reaction [Triiodothyronine results in increased expression of ADRB2 protein] Triiodothyronine results in increased expression of ADRB2 mRNA; Triiodothyronine results in increased expression of ADRB2 protein |
CTD |
PMID:18454446 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions decreases expression increases expression |
EXP |
Amiodarone inhibits the reaction [Triiodothyronine results in decreased expression of ADRB3 protein] Triiodothyronine results in decreased expression of ADRB3 mRNA; Triiodothyronine results in decreased expression of ADRB3 protein Triiodothyronine results in increased expression of ADRB3 protein |
CTD |
PMID:8836703 PMID:10217540 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
Triiodothyronine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of AHR mRNA] |
CTD |
PMID:28478156 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akap12 |
A-kinase anchoring protein 12 |
increases expression |
ISO |
Triiodothyronine results in increased expression of AKAP12 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886
|
|
G |
Akirin2 |
akirin 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of AKIRIN2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 5:49,108,231...49,122,566
Ensembl chr 5:49,108,220...49,122,568
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of AKR1C1 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of AKR1C2 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
increases expression |
ISO |
Triiodothyronine results in increased expression of AKR1C3 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
EXP ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine results in increased phosphorylation of AKT1 protein]; AKT1 protein affects the reaction [Triiodothyronine affects the expression of TTN mRNA]; Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:16021636 PMID:18096819 PMID:36868496 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Triiodothyronine binds to ALB protein |
CTD |
PMID:21517007 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of ALDH1A3 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
|
|
G |
Aldh3a2 |
aldehyde dehydrogenase 3 family, member A2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ALDH3A2 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281
|
|
G |
Amh |
anti-Mullerian hormone |
multiple interactions |
EXP |
Triiodothyronine affects the reaction [Propylthiouracil affects the expression of AMH mRNA] |
CTD |
PMID:7819453 |
|
NCBI chr 7:8,906,776...8,909,192
Ensembl chr 7:8,906,836...8,909,282
|
|
G |
Angptl8 |
angiopoietin-like 8 |
multiple interactions |
ISO |
[THRA protein co-treated with Triiodothyronine] promotes the reaction [ANGPTL8 protein binds to PLIN3 protein]; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 protein; [THRB protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; ANGPTL8 protein affects the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein] |
CTD |
PMID:24262987 |
|
NCBI chr 8:20,376,462...20,378,488
Ensembl chr 8:20,376,462...20,378,490
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of APOA1 protein |
CTD |
PMID:6816881 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoa4 |
apolipoprotein A4 |
multiple interactions |
EXP |
Triiodothyronine results in increased expression of [APOE protein co-treated with APOA4 protein] |
CTD |
PMID:6816881 |
|
NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
EXP |
Triiodothyronine results in increased expression of [APOE protein co-treated with APOA4 protein] |
CTD |
PMID:6816881 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
decreases expression multiple interactions |
ISO EXP |
Triiodothyronine results in decreased expression of APP mRNA; Triiodothyronine results in decreased expression of APP protein Tretinoin promotes the reaction [Triiodothyronine results in decreased secretion of APP protein] Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of APP protein modified form] |
CTD |
PMID:17199430 PMID:36868496 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp1 |
aquaporin 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of AQP1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp8 |
aquaporin 8 |
increases expression |
EXP |
Triiodothyronine results in increased expression of AQP8 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:177,993,313...177,999,158
Ensembl chr 1:177,993,305...177,999,158
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Triiodothyronine inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein] |
CTD |
PMID:33049310 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arhgef25 |
Rho guanine nucleotide exchange factor 25 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of ARHGEF25 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 7:63,005,938...63,013,325
Ensembl chr 7:63,005,940...63,013,719
|
|
G |
Arl4d |
ADP-ribosylation factor like GTPase 4D |
increases expression |
ISO |
Triiodothyronine results in increased expression of ARL4D mRNA |
CTD |
PMID:25172293 |
|
NCBI chr10:86,592,054...86,602,843
Ensembl chr10:86,595,661...86,602,836
|
|
G |
Arrdc3 |
arrestin domain containing 3 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ARRDC3 mRNA |
CTD |
PMID:28299817 |
|
NCBI chr 2:11,137,464...11,149,978
Ensembl chr 2:11,137,460...11,149,978
|
|
G |
Aspg |
asparaginase |
increases expression |
EXP |
Triiodothyronine results in increased expression of ASPG mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 6:131,176,727...131,196,268
Ensembl chr 6:131,176,874...131,196,268
|
|
G |
Aspm |
assembly factor for spindle microtubules |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of ASPM mRNA |
CTD |
PMID:23397585 |
|
NCBI chr13:51,074,849...51,123,755
Ensembl chr13:51,074,849...51,123,755
|
|
G |
Atg5 |
autophagy related 5 |
increases expression affects response to substance |
ISO |
Triiodothyronine results in increased expression of ATG5 mRNA; Triiodothyronine results in increased expression of ATG5 protein ATG5 protein affects the susceptibility to Triiodothyronine |
CTD |
PMID:30209975 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atg7 |
autophagy related 7 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ATG7 mRNA |
CTD |
PMID:30209975 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atp1b2 |
ATPase Na+/K+ transporting subunit beta 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ATP1B2 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr10:54,318,698...54,324,933
Ensembl chr10:54,318,701...54,324,933
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
multiple interactions increases expression |
EXP |
THRB protein promotes the reaction [Triiodothyronine results in increased expression of ATP2A2 mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of ATP2A2 mRNA] |
CTD |
PMID:11577024 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Avp |
arginine vasopressin |
multiple interactions |
EXP |
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA] |
CTD |
PMID:11742803 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bace1 |
beta-secretase 1 |
multiple interactions |
EXP |
Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of BACE1 protein] |
CTD |
PMID:36868496 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bad |
BCL2-associated agonist of cell death |
decreases expression |
ISO EXP |
Triiodothyronine results in decreased expression of BAD protein |
CTD |
PMID:16021636 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression |
ISO EXP |
Triiodothyronine results in decreased expression of BAX protein |
CTD |
PMID:16021636 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
Triiodothyronine promotes the reaction [tamibarotene results in decreased expression of BCL2 mRNA] Triiodothyronine results in increased expression of BCL2 protein |
CTD |
PMID:11201846 PMID:16021636 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
multiple interactions |
ISO |
Triiodothyronine promotes the reaction [tamibarotene results in increased expression of BCL2A1A mRNA] |
CTD |
PMID:11201846 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression |
ISO EXP |
Triiodothyronine results in increased expression of BCL2L1 protein |
CTD |
PMID:16021636 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl3 |
BCL3, transcription coactivator |
increases expression |
EXP |
Triiodothyronine results in increased expression of BCL3 mRNA |
CTD |
PMID:22015988 |
|
NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of BMP2 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions decreases expression |
ISO |
4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in decreased expression of BMP6 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in decreased expression of BMP6 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in decreased expression of BMP6 mRNA] |
CTD |
PMID:14761676 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions |
ISO |
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA |
CTD |
PMID:33091441 |
|
NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Capns1 |
calpain, small subunit 1 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of CAPNS1 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 1:85,444,613...85,454,861
Ensembl chr 1:85,444,608...85,454,795
|
|
G |
Casp3 |
caspase 3 |
decreases expression multiple interactions |
EXP ISO |
Triiodothyronine results in decreased expression of CASP3 protein THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased cleavage of CASP3 protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CASP3 mRNA]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased cleavage of CASP3 protein]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CASP3 mRNA] |
CTD |
PMID:16021636 PMID:32223187 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
EXP |
[Triiodothyronine co-treated with Hexachlorocyclohexane] results in decreased activity of CAT protein; gadolinium chloride inhibits the reaction [[Triiodothyronine co-treated with Hexachlorocyclohexane] results in decreased activity of CAT protein]; Resveratrol inhibits the reaction [Triiodothyronine results in decreased activity of CAT protein] |
CTD |
PMID:12516873 PMID:23391542 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccdc71 |
coiled-coil domain containing 71 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of CCDC71 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 8:109,146,650...109,161,749
Ensembl chr 8:109,146,359...109,165,216
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions increases expression |
ISO |
4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of CCL5 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of CCL5 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of CCL5 mRNA] |
CTD |
PMID:14761676 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccna2 |
cyclin A2 |
increases expression |
ISO EXP |
Triiodothyronine results in increased expression of CCNA2 protein |
CTD |
PMID:16021636 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression multiple interactions |
ISO EXP |
Triiodothyronine results in increased expression of CCND1 protein Triiodothyronine results in increased expression of CCND1 mRNA; Triiodothyronine results in increased expression of CCND1 protein THRB protein promotes the reaction [Triiodothyronine results in increased expression of CCND1 protein]; U 0126 inhibits the reaction [Triiodothyronine results in increased expression of CCND1 mRNA] |
CTD |
PMID:16021636 PMID:20638743 PMID:28315333 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
increases expression |
ISO EXP |
Triiodothyronine results in increased expression of CCNE1 protein Triiodothyronine results in increased expression of CCNE1 mRNA; Triiodothyronine results in increased expression of CCNE1 protein |
CTD |
PMID:16021636 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdc45 |
cell division cycle 45 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of CDC45 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of CDKN1A mRNA; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of CDKN1A mRNA]; Triiodothyronine analog inhibits the reaction [CDKN1A protein binds to PCNA protein]; Triiodothyronine inhibits the reaction [CDKN1A protein binds to PCNA protein] |
CTD |
PMID:14761676 PMID:22383522 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression multiple interactions |
EXP ISO |
Triiodothyronine results in decreased expression of CDKN1B mRNA; Triiodothyronine results in decreased expression of CDKN1B protein THRB protein promotes the reaction [Triiodothyronine results in decreased expression of CDKN1B protein] |
CTD |
PMID:16021636 PMID:20638743 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein] |
CTD |
PMID:33476690 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cep15 |
centrosomal protein 15 |
increases expression |
EXP |
Triiodothyronine results in increased expression of CEP15 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr15:12,815,159...12,835,115
Ensembl chr15:12,818,385...12,833,838
|
|
G |
Ces2c |
carboxylesterase 2C |
increases expression |
EXP |
Triiodothyronine results in increased expression of CES2C mRNA |
CTD |
PMID:28299817 |
|
NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions decreases expression |
EXP |
Phenelzine inhibits the reaction [Triiodothyronine results in decreased expression of CGA mRNA]; Triiodothyronine inhibits the reaction [Phenelzine results in increased expression of CGA mRNA] |
CTD |
PMID:20148560 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases phosphorylation |
ISO |
Triiodothyronine analog results in increased phosphorylation of CHEK1 protein |
CTD |
PMID:22383522 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chst1 |
carbohydrate sulfotransferase 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of CHST1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 3:78,552,059...78,574,740
Ensembl chr 3:78,548,525...78,574,883
|
|
G |
Clu |
clusterin |
increases expression |
EXP |
Triiodothyronine results in increased expression of CLU mRNA |
CTD |
PMID:7531505 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
multiple interactions increases expression |
EXP |
ciglitazone inhibits the reaction [Triiodothyronine results in increased expression of COL10A1 mRNA]; troglitazone inhibits the reaction [Triiodothyronine results in increased expression of COL10A1 mRNA] |
CTD |
PMID:16023420 |
|
NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions increases expression |
EXP |
Triiodothyronine promotes the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] Triiodothyronine results in increased expression of COL1A1 mRNA |
CTD |
PMID:18031379 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col6a3 |
collagen type VI alpha 3 chain |
increases expression |
ISO |
Triiodothyronine results in increased expression of COL6A3 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471
|
|
G |
Coq10b |
coenzyme Q10B |
increases expression |
EXP |
Triiodothyronine results in increased expression of COQ10B mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 9:56,553,751...56,573,671
Ensembl chr 9:56,553,758...56,573,663
|
|
G |
Cox4i1 |
cytochrome c oxidase subunit 4i1 |
multiple interactions increases expression |
ISO |
Chloroquine promotes the reaction [Triiodothyronine results in increased expression of COX4I1 protein] |
CTD |
PMID:30209975 |
|
NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression multiple interactions |
ISO EXP |
Triiodothyronine results in increased expression of CPT1A mRNA [BMS201038 co-treated with Triiodothyronine] results in increased expression of CPT1A mRNA; Resveratrol promotes the reaction [Triiodothyronine results in increased expression of CPT1A mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A protein]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA] resveratrol promotes the reaction [Triiodothyronine results in increased expression of CPT1A mRNA] Triiodothyronine results in increased expression of CPT1A mRNA; Triiodothyronine results in increased expression of CPT1A protein |
CTD |
PMID:23209300 PMID:25048947 PMID:34902352 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
increases expression |
ISO |
Triiodothyronine results in increased expression of CPT1B mRNA |
CTD |
PMID:30209975 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Cracr2b |
calcium release activated channel regulator 2B |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of CRACR2B mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 1:196,558,407...196,563,961
Ensembl chr 1:196,558,588...196,563,771
|
|
G |
Crat |
carnitine O-acetyltransferase |
increases expression |
EXP |
Triiodothyronine results in increased expression of CRAT mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255
|
|
G |
Cs |
citrate synthase |
multiple interactions decreases activity |
ISO EXP |
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA Triiodothyronine results in decreased activity of CS protein |
CTD |
PMID:1153425 PMID:33091441 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Csad |
cysteine sulfinic acid decarboxylase |
increases expression |
EXP |
Triiodothyronine results in increased expression of CSAD mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 7:133,308,571...133,337,914
Ensembl chr 7:133,308,574...133,337,615
|
|
G |
Csk |
C-terminal Src kinase |
multiple interactions |
ISO |
CSK protein promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine binds to THRA protein]] |
CTD |
PMID:9664232 |
|
NCBI chr 8:58,029,748...58,048,742
Ensembl chr 8:58,029,749...58,048,292
|
|
G |
Ctse |
cathepsin E |
increases expression |
EXP |
Triiodothyronine results in increased expression of CTSE mRNA |
CTD |
PMID:15953391 |
|
NCBI chr13:43,091,954...43,114,509
Ensembl chr13:43,092,128...43,114,502
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CYCS mRNA]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CYCS mRNA] |
CTD |
PMID:32223187 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein] |
CTD |
PMID:21726595 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein] |
CTD |
PMID:21726595 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
Chlorpyrifos inhibits the reaction [Triiodothyronine results in increased expression of CYP19A1 mRNA]; Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:34571837 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
Triiodothyronine affects the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Triiodothyronine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] Triiodothyronine results in increased expression of CYP1A1 mRNA |
CTD |
PMID:28478156 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of CYP1A2 mRNA Triiodothyronine affects the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA]; Triiodothyronine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 protein] |
CTD |
PMID:28478156 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of CYP24A1 mRNA (4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of CYP24A1 mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases activity increases expression |
EXP |
Triiodothyronine results in increased activity of CYP2E1 protein Triiodothyronine results in increased expression of CYP2E1 protein |
CTD |
PMID:14631868 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of CYP3A4 mRNA SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
decreases expression |
EXP |
Triiodothyronine results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:10393316 PMID:29357290 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dbp |
D-box binding PAR bZIP transcription factor |
increases expression |
ISO |
Triiodothyronine results in increased expression of DBP mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745
|
|
G |
Decr2 |
2,4-dienoyl-CoA reductase 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of DECR2 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr10:15,104,907...15,113,281
Ensembl chr10:15,002,926...15,118,479
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
affects abundance increases chemical synthesis multiple interactions increases expression affects metabolic processing |
ISO EXP |
DIO1 gene SNP affects the abundance of Triiodothyronine DIO1 protein results in increased chemical synthesis of Triiodothyronine Arsenic affects the reaction [Triiodothyronine results in increased expression of DIO1 mRNA]; Pentachlorophenol inhibits the reaction [Triiodothyronine results in increased expression of DIO1 mRNA] DIO1 protein affects the metabolism of Triiodothyronine [DIO1 protein co-treated with DIO2 protein co-treated with DIO3 protein] affects the abundance of Triiodothyronine; [DIO1 protein results in increased metabolism of Thyroxine] which results in increased abundance of Triiodothyronine; Iodoacetates inhibits the reaction [[DIO1 protein results in increased metabolism of Thyroxine] which results in increased abundance of Triiodothyronine] 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Triiodothyronine results in increased expression of DIO1 mRNA] |
CTD |
PMID:15254343 PMID:16131326 PMID:17105838 PMID:18288313 PMID:21565810 PMID:23397585 PMID:24001430 PMID:25646720 PMID:27420076 PMID:28167136 PMID:29357290 More...
|
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions increases chemical synthesis increases expression decreases expression |
ISO EXP |
2,2',4,4',5-brominated diphenyl ether inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; 2,2',4,4',5-brominated diphenyl ether metabolite inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; 2,2',4,4'-tetrabromodiphenyl ether metabolite inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; [DIO1 protein co-treated with DIO2 protein co-treated with DIO3 protein] affects the abundance of Triiodothyronine; [DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine; kaempferol promotes the reaction [DIO2 protein results in increased activity of and results in increased abundance of Triiodothyronine] DIO2 protein results in increased chemical synthesis of Triiodothyronine Triiodothyronine results in increased expression of DIO2 mRNA [Chlorpyrifos co-treated with Triiodothyronine] results in decreased expression of DIO2 mRNA; [Ethylenethiourea co-treated with Triiodothyronine] results in decreased expression of DIO2 mRNA Triiodothyronine results in decreased expression of DIO2 mRNA |
CTD |
PMID:17327447 PMID:17615150 PMID:23397585 PMID:25646720 PMID:26004626 PMID:34571837 More...
|
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of DIO3 mRNA [Aurothioglucose results in decreased activity of DIO3 protein] which affects the metabolism of Triiodothyronine; [DIO1 protein co-treated with DIO2 protein co-treated with DIO3 protein] affects the abundance of Triiodothyronine; [xanthohumol results in decreased activity of DIO3 protein] which affects the metabolism of Triiodothyronine Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of DIO3 mRNA] |
CTD |
PMID:23397585 PMID:25962824 PMID:34571837 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dlx2 |
distal-less homeobox 2 |
multiple interactions |
ISO |
[pyriproxyfen metabolite co-treated with Triiodothyronine] results in increased expression of DLX2 mRNA |
CTD |
PMID:34289950 |
|
NCBI chr 3:56,370,238...56,373,581
Ensembl chr 3:56,370,483...56,373,597
|
|
G |
Dmbt1 |
deleted in malignant brain tumors 1 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of DMBT1 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 1:185,617,469...185,696,476
Ensembl chr 1:185,617,294...185,696,478
|
|
G |
Dmpk |
DM1 protein kinase |
increases expression |
EXP |
Triiodothyronine results in increased expression of DMPK mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:78,730,255...78,740,585
Ensembl chr 1:78,730,275...78,740,593
|
|
G |
Dmtn |
dematin actin binding protein |
increases expression |
ISO |
Triiodothyronine results in increased expression of DMTN mRNA |
CTD |
PMID:25172293 |
|
NCBI chr15:45,677,974...45,702,261
Ensembl chr15:45,677,977...45,705,601
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
multiple interactions decreases expression |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of DUSP2 mRNA; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in decreased expression of DUSP2 mRNA] |
CTD |
PMID:14761676 |
|
NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499
|
|
G |
Dync1li2 |
dynein, cytoplasmic 1 light intermediate chain 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of DYNC1LI2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr19:531,783...554,670
Ensembl chr19:531,812...554,670
|
|
G |
Ech1 |
enoyl-CoA hydratase 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ECH1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795
|
|
G |
Efcab3 |
EF-hand calcium binding domain 3 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of EFCAB3 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr10:89,583,526...90,077,260
Ensembl chr10:89,644,522...90,077,259
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
EXP ISO |
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA] Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11742803 PMID:16150908 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
decreases phosphorylation |
ISO |
Triiodothyronine results in decreased phosphorylation of EIF4EBP1 protein |
CTD |
PMID:30209975 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Eml2 |
EMAP like 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of EML2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 1:78,827,595...78,859,342
Ensembl chr 1:78,828,080...78,859,341
|
|
G |
Eno1 |
enolase 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ENO1 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of EPAS1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Epb41l3 |
erythrocyte membrane protein band 4.1-like 3 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of EPB41L3 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:109,016,113...109,260,607
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Triiodothyronine results in increased expression of EREG mRNA |
CTD |
PMID:32816093 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions decreases expression increases expression |
ISO |
Tamoxifen inhibits the reaction [Triiodothyronine results in decreased expression of ESR1 mRNA]; Triiodothyronine binds to and results in increased activity of ESR1 protein Triiodothyronine results in increased expression of ESR1 mRNA [Chlorpyrifos co-treated with Triiodothyronine] results in increased expression of ESR1 mRNA; Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of ESR1 mRNA] |
CTD |
PMID:19942988 PMID:33049310 PMID:34571837 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
EXP ISO |
[Arsenic co-treated with Estradiol co-treated with Triiodothyronine] results in decreased expression of ESR2 mRNA; [bisphenol A co-treated with Estradiol co-treated with Triiodothyronine] results in increased expression of ESR2 mRNA; [bisphenol A co-treated with Zearalenone co-treated with Arsenic co-treated with enzacamene co-treated with Estradiol co-treated with Triiodothyronine] results in decreased expression of ESR2 mRNA; [bisphenol A results in increased susceptibility to [Estradiol co-treated with Triiodothyronine]] which results in increased expression of ESR2 mRNA; [enzacamene co-treated with Estradiol co-treated with Triiodothyronine] affects the expression of ESR2 mRNA; [Estradiol co-treated with Triiodothyronine] inhibits the reaction [bisphenol A results in decreased expression of ESR2 mRNA]; [Estradiol co-treated with Triiodothyronine] promotes the reaction [Zearalenone results in decreased expression of ESR2 mRNA]; [Zearalenone co-treated with Estradiol co-treated with Triiodothyronine] results in decreased expression of ESR2 mRNA; [Zearalenone results in increased susceptibility to [Estradiol co-treated with Triiodothyronine]] which results in decreased expression of ESR2 mRNA Triiodothyronine binds to and results in increased activity of ESR2 protein |
CTD |
PMID:27338438 PMID:33049310 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Ethe1 |
ETHE1, persulfide dioxygenase |
increases expression |
EXP |
Triiodothyronine results in increased expression of ETHE1 mRNA |
CTD |
PMID:28299817 |
|
NCBI chr 1:80,184,037...80,199,092
Ensembl chr 1:80,183,894...80,199,052
|
|
G |
Eva1c |
eva-1 homolog C |
increases expression |
ISO |
Triiodothyronine results in increased expression of EVA1C mRNA |
CTD |
PMID:25172293 |
|
NCBI chr11:30,089,510...30,163,596
Ensembl chr11:30,089,365...30,163,596
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression multiple interactions |
EXP ISO |
Triiodothyronine results in increased expression of FABP4 mRNA [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA] |
CTD |
PMID:15953391 PMID:33476690 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
increases expression |
EXP |
Triiodothyronine results in increased expression of FABP5 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Fads2 |
fatty acid desaturase 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of FADS2 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Fam171b |
family with sequence similarity 171, member B |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of FAM171B mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 3:68,930,755...68,986,113
Ensembl chr 3:68,930,822...68,986,127
|
|
G |
Fam83h |
family with sequence similarity 83, member H |
increases expression |
ISO |
Triiodothyronine results in increased expression of FAM83H mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 7:107,716,431...107,724,619
Ensembl chr 7:107,716,431...107,728,672
|
|
G |
Fasn |
fatty acid synthase |
increases expression multiple interactions |
EXP ISO |
Triiodothyronine results in increased expression of FASN mRNA [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA] [pyriproxyfen metabolite co-treated with Triiodothyronine] results in increased expression of FASN mRNA |
CTD |
PMID:15953391 PMID:33476690 PMID:34289950 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of FDFT1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fdps |
farnesyl diphosphate synthase |
increases expression |
EXP |
Triiodothyronine results in increased expression of FDPS mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
multiple interactions |
EXP |
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA] |
CTD |
PMID:11742803 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgf18 |
fibroblast growth factor 18 |
multiple interactions |
ISO |
Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16150908 |
|
NCBI chr10:17,706,011...17,737,702
Ensembl chr10:17,706,174...17,736,818
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO EXP |
Triiodothyronine inhibits the reaction [FGF2 protein results in increased phosphorylation of STAT1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein] [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; Triiodothyronine promotes the reaction [FGF2 protein promotes the reaction [FGFR1 protein results in increased phosphorylation of FGFR1 protein]]; Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:11742803 PMID:12805413 PMID:16150908 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of FGF7 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions |
ISO |
Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16150908 |
|
NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
increases expression multiple interactions |
ISO EXP |
Triiodothyronine results in increased expression of FGFR1 mRNA Cycloheximide inhibits the reaction [Triiodothyronine results in increased expression of FGFR1 mRNA]; Dactinomycin inhibits the reaction [Triiodothyronine results in increased expression of FGFR1 mRNA]; Triiodothyronine promotes the reaction [FGF2 protein promotes the reaction [FGFR1 protein results in increased phosphorylation of FGFR1 protein]] Triiodothyronine results in increased expression of FGFR1 mRNA; Triiodothyronine results in increased expression of FGFR1 protein |
CTD |
PMID:12805413 PMID:16150908 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of FGFR2 mRNA |
CTD |
PMID:16150908 |
|
NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
increases expression |
ISO |
Triiodothyronine results in increased expression of FGFR3 mRNA |
CTD |
PMID:16150908 |
|
NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
|
|
G |
Fkbp10 |
FKBP prolyl isomerase 10 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of FKBP10 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr10:85,345,434...85,357,998
Ensembl chr10:85,346,126...85,427,330
|
|
G |
Flrt1 |
fibronectin leucine rich transmembrane protein 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of FLRT1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 1:204,275,785...204,292,844
Ensembl chr 1:204,275,367...204,353,750
|
|
G |
Foxo6 |
forkhead box O6 |
increases expression |
ISO |
Triiodothyronine results in increased expression of FOXO6 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 5:133,856,087...133,876,387
Ensembl chr 5:133,856,072...133,876,573
|
|
G |
Fpgs |
folylpolyglutamate synthase |
increases expression |
EXP |
Triiodothyronine results in increased expression of FPGS mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 3:15,972,800...15,993,592
Ensembl chr 3:15,972,800...15,993,563
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
FSHB protein promotes the reaction [Triiodothyronine results in increased expression of INHBB mRNA]; Triiodothyronine promotes the reaction [FSHB protein results in increased expression of INHBB mRNA] |
CTD |
PMID:7531505 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of FXYD2 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 8:45,712,901...45,720,032
Ensembl chr 8:45,712,903...45,720,203
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions increases expression |
ISO |
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of G6PC1 mRNA]; SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of G6PC1 mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gap43 |
growth associated protein 43 |
increases expression |
EXP |
Triiodothyronine results in increased expression of GAP43 mRNA; Triiodothyronine results in increased expression of GAP43 protein |
CTD |
PMID:15708448 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gba1 |
glucosylceramidase beta 1 |
increases activity |
EXP |
Triiodothyronine results in increased activity of GBA1 protein |
CTD |
PMID:9101438 |
|
NCBI chr 2:174,609,437...174,615,457
Ensembl chr 2:174,609,403...174,618,263
|
|
G |
Gch1 |
GTP cyclohydrolase 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of GCH1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions increases expression |
EXP ISO |
Alitretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Amiodarone inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; bisphenol A promotes the reaction [Triiodothyronine results in increased expression of and results in increased secretion of GH protein]; Butyric Acid inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Dexamethasone promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Edetic Acid promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of and results in increased secretion of GH protein]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 protein]; Pentetic Acid promotes the reaction [Alitretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Tretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Tretinoin results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Polybrominated Biphenyls analog inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Polybrominated Biphenyls analog inhibits the reaction [Triiodothyronine results in increased expression of GH1 protein]; Tretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Triiodothyronine promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]; Triiodothyronine promotes the reaction [Tretinoin results in increased expression of GH1 mRNA]; Triiodothyronine results in increased expression of and results in increased secretion of GH protein; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Alitretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Tretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Tretinoin results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]] Triiodothyronine results in increased expression of GH mRNA; Triiodothyronine results in increased expression of GH1 mRNA; Triiodothyronine results in increased expression of GH1 protein |
CTD |
PMID:2211641 PMID:2910914 PMID:10720163 PMID:15240998 PMID:17090972 PMID:17928132 PMID:22201216 PMID:24001430 PMID:27420076 More...
|
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Ghrh |
growth hormone releasing hormone |
multiple interactions |
EXP |
Triiodothyronine promotes the reaction [Dexamethasone results in increased expression of GHRH mRNA] |
CTD |
PMID:17090972 |
|
NCBI chr 3:145,992,762...146,012,528
Ensembl chr 3:145,992,763...146,011,889
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression multiple interactions |
EXP ISO |
Triiodothyronine results in increased expression of GJA1 protein Triiodothyronine results in increased expression of GJA1 mRNA [Triiodothyronine co-treated with Chlorpyrifos] results in increased expression of GJA1 mRNA; [Triiodothyronine co-treated with Ethylenethiourea] results in increased expression of GJA1 mRNA |
CTD |
PMID:15685554 PMID:34571837 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gpcpd1 |
glycerophosphocholine phosphodiesterase 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of GPCPD1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 3:119,787,681...119,832,550
Ensembl chr 3:119,787,682...119,832,517
|
|
G |
Gpd2 |
glycerol-3-phosphate dehydrogenase 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of GPD2 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Triiodothyronine inhibits the reaction [BMS201038 results in increased expression of GPT protein] |
CTD |
PMID:34902352 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
multiple interactions |
EXP |
Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of GPX3 protein] |
CTD |
PMID:36868496 |
|
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Grik4 |
glutamate ionotropic receptor kainate type subunit 4 |
increases expression |
ISO |
Triiodothyronine results in increased expression of GRIK4 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 8:42,903,043...43,331,990
Ensembl chr 8:42,905,056...43,193,751
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:36868496 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
multiple interactions |
EXP |
Triiodothyronine inhibits the reaction [goitrin results in increased expression of GSTA2 protein] |
CTD |
PMID:7532609 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
EXP |
Triiodothyronine inhibits the reaction [goitrin results in increased expression of GSTP1 protein] |
CTD |
PMID:7532609 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstp3 |
glutathione S-transferase pi 3 |
decreases expression |
EXP |
Triiodothyronine results in decreased expression of GSTP3 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 1:201,355,682...201,358,216
Ensembl chr 1:201,355,682...201,358,330
|
|
G |
Gulp1 |
GULP PTB domain containing engulfment adaptor 1 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of GULP1 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 9:46,622,699...46,899,005
Ensembl chr 9:46,622,669...46,899,005
|
|
G |
H1f5 |
H1.5 linker histone, cluster member |
increases expression |
ISO |
Triiodothyronine results in increased expression of H1-5 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr17:42,726,132...42,727,162
Ensembl chr17:42,726,127...42,769,160
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation multiple interactions |
ISO |
Triiodothyronine analog results in increased phosphorylation of H2AX protein Triiodothyronine analog promotes the reaction [Cisplatin results in increased expression of H2AX protein] |
CTD |
PMID:22383522 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hba-a1 |
hemoglobin alpha, adult chain 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of HBA-A1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr10:15,337,265...15,338,121
Ensembl chr10:15,307,815...15,338,392
|
|
G |
Hbb |
hemoglobin subunit beta |
increases expression |
EXP |
Triiodothyronine results in increased expression of HBB mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012
|
|
G |
Hbg1 |
hemoglobin subunit gamma 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of HBG1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:158,271,871...158,273,426
Ensembl chr 1:158,271,873...158,273,425
|
|
G |
Hcn2 |
hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of HCN2 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 7:9,969,801...9,988,839
Ensembl chr 7:9,970,368...9,988,841
|
|
G |
Hdc |
histidine decarboxylase |
decreases expression |
EXP |
Triiodothyronine results in decreased expression of HDC mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 3:113,847,256...113,865,334
Ensembl chr 3:113,847,260...113,865,341
|
|
G |
Heg1 |
heart development protein with EGF-like domains 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of HEG1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr11:67,006,954...67,095,020
Ensembl chr11:66,957,190...67,095,051
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
ISO |
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA |
CTD |
PMID:33091441 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
Triiodothyronine results in increased expression of HIF1A mRNA |
CTD |
PMID:15507505 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Higd1a |
HIG1 hypoxia inducible domain family, member 1A |
increases expression |
EXP |
Triiodothyronine results in increased expression of HIGD1A mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 8:121,514,152...121,523,382
Ensembl chr 8:121,514,156...121,523,443
|
|
G |
Hira |
histone cell cycle regulator |
increases expression |
ISO |
Triiodothyronine results in increased expression of HIRA mRNA |
CTD |
PMID:23397585 |
|
NCBI chr11:82,024,469...82,133,212
Ensembl chr11:82,024,469...82,133,529
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of HMGCS1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of HMGCS2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of HMOX1 protein] |
CTD |
PMID:36868496 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnph3 |
heterogeneous nuclear ribonucleoprotein H3 |
increases expression |
ISO |
Triiodothyronine results in increased expression of HNRNPH3 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr20:25,616,400...25,625,814
Ensembl chr20:25,614,733...25,625,750
|
|
G |
Hr |
HR, lysine demethylase and nuclear receptor corepressor |
increases expression |
ISO |
Triiodothyronine results in increased expression of HR mRNA |
CTD |
PMID:25172293 PMID:26096596 |
|
NCBI chr15:45,626,835...45,646,313
Ensembl chr15:45,626,835...45,646,313
|
|
G |
Hscb |
HscB mitochondrial iron-sulfur cluster co-chaperone |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of HSCB mRNA |
CTD |
PMID:23397585 |
|
NCBI chr12:45,821,527...45,831,902
Ensembl chr12:45,821,555...45,831,909
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; Triiodothyronine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]; Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA] |
CTD |
PMID:21726595 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hunk |
hormonally upregulated Neu-associated kinase |
increases expression |
ISO |
Triiodothyronine results in increased expression of HUNK mRNA |
CTD |
PMID:25172293 |
|
NCBI chr11:29,641,122...29,758,392
Ensembl chr11:29,640,775...29,757,526
|
|
G |
Idh1 |
isocitrate dehydrogenase (NADP(+)) 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of IDH1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 9:66,534,146...66,563,703
Ensembl chr 9:66,534,146...66,563,708
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions increases secretion increases expression |
EXP |
Estradiol inhibits the reaction [Triiodothyronine results in increased expression of IGF1 mRNA]; Estradiol inhibits the reaction [Triiodothyronine results in increased secretion of IGF1 protein] |
CTD |
PMID:7684602 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of IGFBP2 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
|
|
G |
Iglon5 |
IgLON family member 5 |
increases expression |
ISO |
Triiodothyronine results in increased expression of IGLON5 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 1:93,880,906...93,898,929
Ensembl chr 1:93,881,991...93,898,754
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Triiodothyronine results in increased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO EXP |
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL1B mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL1B protein]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL1B mRNA]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL1B protein] Triiodothyronine results in increased expression of IL1B mRNA Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of IL1B protein]; Triiodothyronine inhibits the reaction [Propylthiouracil results in increased expression of IL1B protein] |
CTD |
PMID:29796989 PMID:32223187 PMID:32816093 PMID:33476690 PMID:36868496 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
Triiodothyronine results in increased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL6 mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL6 protein]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL6 mRNA]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL6 protein] Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of IL6 protein]; Triiodothyronine inhibits the reaction [Propylthiouracil results in increased expression of IL6 mRNA] |
CTD |
PMID:29796989 PMID:32223187 PMID:36868496 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inha |
inhibin subunit alpha |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of INHA mRNA |
CTD |
PMID:34571837 |
|
NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248
|
|
G |
Inhbb |
inhibin subunit beta B |
multiple interactions increases expression |
EXP |
FSHB protein promotes the reaction [Triiodothyronine results in increased expression of INHBB mRNA]; Triiodothyronine promotes the reaction [FSHB protein results in increased expression of INHBB mRNA] |
CTD |
PMID:7531505 |
|
NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
(+)-JQ1 compound inhibits the reaction [[Triiodothyronine co-treated with Rosiglitazone co-treated with INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of UCP1 mRNA]; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA; [Triiodothyronine co-treated with Rosiglitazone co-treated with INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of UCP1 mRNA |
CTD |
PMID:26972250 PMID:33091441 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 protein [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA] |
CTD |
PMID:27605626 PMID:33476690 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insig1 |
insulin induced gene 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of INSIG1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of IRF1 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
Triiodothyronine promotes the reaction [tamibarotene results in increased expression of ITGAM protein] |
CTD |
PMID:11201846 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions |
ISO |
ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]] |
CTD |
PMID:22227104 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Itgb5 |
integrin subunit beta 5 |
increases expression decreases expression |
ISO |
Triiodothyronine results in increased expression of ITGB5 mRNA Triiodothyronine results in decreased expression of ITGB5 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr11:66,828,428...66,944,231
Ensembl chr11:66,829,285...66,944,472
|
|
G |
Itpk1 |
inositol-tetrakisphosphate 1-kinase |
increases expression |
ISO |
Triiodothyronine results in increased expression of ITPK1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 6:121,710,750...121,844,501
Ensembl chr 6:121,710,755...121,844,107
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ITPR1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491
|
|
G |
Kantr |
KANTR integral membrane protein |
increases expression |
ISO |
Triiodothyronine results in increased expression of KANTR mRNA |
CTD |
PMID:25172293 |
|
NCBI chr X:21,402,717...21,430,663
|
|
G |
Kcna1 |
potassium voltage-gated channel subfamily A member 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of KCNA1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 4:159,464,223...159,472,905
Ensembl chr 4:159,464,188...159,472,682
|
|
G |
Kcna4 |
potassium voltage-gated channel subfamily A member 4 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of KCNA4 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 3:93,756,399...93,778,004
Ensembl chr 3:93,756,446...93,769,162
|
|
G |
Kcnma1 |
potassium calcium-activated channel subfamily M alpha 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 protein |
CTD |
PMID:27605626 |
|
NCBI chr15:302,480...1,007,675
Ensembl chr15:302,214...1,001,198
|
|
G |
Kctd12 |
potassium channel tetramerization domain containing 12 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of KCTD12 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr15:79,800,078...79,806,017
Ensembl chr15:79,801,191...79,806,282
|
|
G |
Kif1b |
kinesin family member 1B |
increases expression |
EXP |
Triiodothyronine results in increased expression of KIF1B mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 5:159,607,697...159,742,778
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Klf9 |
KLF transcription factor 9 |
decreases expression increases expression |
ISO |
Triiodothyronine results in decreased expression of KLF9 mRNA Triiodothyronine results in increased expression of KLF9 mRNA |
CTD |
PMID:15507505 PMID:23397585 PMID:26096596 PMID:35172007 |
|
NCBI chr 1:220,700,108...220,725,110
Ensembl chr 1:220,700,108...220,725,037
|
|
G |
Krt13 |
keratin 13 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of KRT13 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr10:85,051,887...85,056,099
Ensembl chr10:85,051,889...85,056,084
|
|
G |
Kyat1 |
kynurenine aminotransferase 1 |
decreases activity |
EXP |
Triiodothyronine results in decreased activity of KYAT1 protein |
CTD |
PMID:32663543 |
|
NCBI chr 3:13,459,598...13,493,308
Ensembl chr 3:13,459,591...13,493,355
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions increases expression |
ISO EXP |
Amiodarone promotes the reaction [Triiodothyronine results in increased expression of LDLR mRNA]; desethylamiodarone promotes the reaction [Triiodothyronine results in increased expression of LDLR mRNA] Triiodothyronine inhibits the reaction [Amiodarone results in decreased expression of LDLR protein] |
CTD |
PMID:9071962 PMID:9712728 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lgi4 |
leucine-rich repeat LGI family, member 4 |
increases expression |
ISO |
Triiodothyronine results in increased expression of LGI4 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 1:86,294,539...86,305,909
Ensembl chr 1:86,295,074...86,304,874
|
|
G |
Lhx3 |
LIM homeobox 3 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of LHX3 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 3:9,026,432...9,035,122
Ensembl chr 3:9,027,425...9,034,480
|
|
G |
Lipe |
lipase E, hormone sensitive type |
increases expression |
ISO |
Triiodothyronine results in increased expression of LIPE mRNA |
CTD |
PMID:30209975 |
|
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Lmcd1 |
LIM and cysteine-rich domains 1 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of LMCD1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 4:145,393,153...145,452,049
Ensembl chr 4:145,393,145...145,452,046
|
|
G |
Lpin3 |
lipin 3 |
increases expression |
ISO |
Triiodothyronine results in increased expression of LPIN3 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 3:149,533,719...149,558,494
Ensembl chr 3:149,534,051...149,558,327
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
EXP |
Triiodothyronine results in increased expression of LPL mRNA |
CTD |
PMID:15953391 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrp1 |
LDL receptor related protein 1 |
multiple interactions |
ISO |
Triiodothyronine inhibits the reaction [[Iodine deficiency co-treated with Propylthiouracil] results in decreased expression of LRP1 protein] |
CTD |
PMID:23517243 |
|
NCBI chr 7:63,380,325...63,461,029
Ensembl chr 7:63,380,356...63,460,910
|
|
G |
Lss |
lanosterol synthase |
increases expression |
EXP |
Triiodothyronine results in increased expression of LSS mRNA |
CTD |
PMID:15953391 |
|
NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Ltb4r |
leukotriene B4 receptor |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of LTB4R mRNA |
CTD |
PMID:14761676 |
|
NCBI chr15:29,263,199...29,265,716
|
|
G |
Lyrm9 |
LYR motif containing 9 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of LYRM9 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr10:63,725,718...63,739,772
Ensembl chr10:63,725,743...63,739,772
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases lipidation multiple interactions increases expression |
ISO |
Triiodothyronine results in increased lipidation of MAP1LC3B protein bafilomycin A1 promotes the reaction [Triiodothyronine results in increased lipidation of MAP1LC3B protein]; Triiodothyronine promotes the reaction [bafilomycin A1 results in increased lipidation of MAP1LC3B protein] Triiodothyronine results in increased expression of MAP1LC3B mRNA |
CTD |
PMID:30209975 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases expression |
ISO EXP |
Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Triiodothyronine results in increased expression of MAPK1 mRNA] Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12805413 PMID:16150908 PMID:28315333 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases expression |
ISO EXP |
Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK3 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]; Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Triiodothyronine results in increased expression of MAPK3 mRNA] Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12805413 PMID:16150908 PMID:28315333 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of and results in increased phosphorylation of MAPT protein] |
CTD |
PMID:36868496 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mb |
myoglobin |
affects expression |
EXP |
Triiodothyronine affects the expression of MB mRNA |
CTD |
PMID:25098716 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Mbp |
myelin basic protein |
increases expression |
ISO |
Triiodothyronine results in increased expression of MBP protein alternative form |
CTD |
PMID:15345905 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Me1 |
malic enzyme 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ME1 mRNA |
CTD |
PMID:15953391 PMID:29357290 |
|
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
|
|
G |
Meioc |
meiosis specific with coiled-coil domain |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of MEIOC mRNA |
CTD |
PMID:23397585 |
|
NCBI chr10:87,628,807...87,646,485
Ensembl chr10:87,628,875...87,646,752
|
|
G |
Mfsd2a |
MFSD2 lysolipid transporter A, lysophospholipid |
increases expression |
ISO |
Triiodothyronine results in increased expression of MFSD2A mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 5:135,225,801...135,240,744
Ensembl chr 5:135,225,816...135,240,690
|
|
G |
Mier3 |
MIER family member 3 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of MIER3 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 2:43,287,546...43,316,422
Ensembl chr 2:43,287,916...43,316,136
|
|
G |
Minpp1-ps1 |
multiple inositol-polyphosphate phosphatase 1, pseudogene 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of MINPP1-PS1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:74,017,248...74,019,633
Ensembl chr 1:230,354,438...230,379,730
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of MKI67 mRNA U 0126 inhibits the reaction [Triiodothyronine results in increased expression of MKI67 mRNA] |
CTD |
PMID:28315333 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmd2 |
monocyte to macrophage differentiation-associated 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of MMD2 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr12:11,962,733...12,009,776
Ensembl chr12:11,962,757...12,009,773
|
|
G |
Mmp11 |
matrix metallopeptidase 11 |
multiple interactions increases expression |
ISO |
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of MMP11 mRNA]; SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of MMP11 mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr20:12,730,846...12,739,629
Ensembl chr20:12,730,836...12,739,628
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP ISO |
Triiodothyronine inhibits the reaction [TGFB1 protein results in increased secretion of MMP2 protein] [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA |
CTD |
PMID:18031379 PMID:33091441 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
[Triiodothyronine co-treated with Hexachlorocyclohexane] results in increased activity of MPO protein |
CTD |
PMID:7503757 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Msi1 |
musashi RNA-binding protein 1 |
multiple interactions |
ISO |
[pyriproxyfen metabolite co-treated with Triiodothyronine] results in increased expression of MSI1 mRNA |
CTD |
PMID:34289950 |
|
NCBI chr12:41,158,301...41,251,134
Ensembl chr12:41,158,599...41,191,076
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
ISO |
Triiodothyronine results in decreased phosphorylation of MTOR protein |
CTD |
PMID:30209975 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myh6 |
myosin heavy chain 6 |
multiple interactions increases expression |
EXP |
S100A6 protein inhibits the reaction [Triiodothyronine results in increased expression of MYH6 mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of MYH6 mRNA] |
CTD |
PMID:11577024 PMID:15578571 PMID:15652358 |
|
NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions decreases expression |
EXP |
Triiodothyronine inhibits the reaction [Phenylephrine results in increased expression of MYH7 mRNA] Triiodothyronine results in decreased expression of MYH7 mRNA |
CTD |
PMID:11577024 PMID:15578571 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Naglt1 |
Na+ dependent glucose transporter 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of NAGLT1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr20:43,411,550...43,423,873
Ensembl chr20:43,394,843...43,423,873
|
|
G |
Ncapg2 |
non-SMC condensin II complex, subunit G2 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of NCAPG2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 6:137,342,449...137,418,083
Ensembl chr 6:137,342,943...137,415,159
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein; bisphenol A inhibits the reaction [[Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein] |
CTD |
PMID:22227104 |
|
NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
Triiodothyronine promotes the reaction [NCOA2 protein binds to THRA protein]; Triiodothyronine promotes the reaction [NCOA2 protein binds to THRB protein]; Triiodothyronine promotes the reaction [THRA protein binds to NCOA2 protein]; Triiodothyronine promotes the reaction [THRB protein binds to NCOA2 protein] |
CTD |
PMID:29146198 PMID:31566444 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Ncor1 |
nuclear receptor co-repressor 1 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein] |
CTD |
PMID:22227104 |
|
NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
|
|
G |
Ncor2 |
nuclear receptor co-repressor 2 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein] |
CTD |
PMID:22227104 |
|
NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319
|
|
G |
Ndufa5 |
NADH:ubiquinone oxidoreductase subunit A5 |
increases expression |
EXP |
Triiodothyronine results in increased expression of NDUFA5 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 4:52,997,327...53,005,685
Ensembl chr 4:52,995,546...53,005,598
|
|
G |
Nefl |
neurofilament light chain |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of NEFL mRNA |
CTD |
PMID:25172293 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nefm |
neurofilament medium chain |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of NEFM mRNA |
CTD |
PMID:25172293 |
|
NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO EXP |
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of NFE2L2 protein] |
CTD |
PMID:33476690 PMID:36868496 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases activity multiple interactions |
EXP |
Triiodothyronine results in increased activity of NFKB1 protein Hexachlorocyclohexane affects the reaction [Triiodothyronine results in increased activity of NFKB1 protein] |
CTD |
PMID:15019085 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA |
CTD |
PMID:33476690 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nnat |
neuronatin |
decreases expression |
EXP |
Triiodothyronine results in decreased expression of NNAT mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 3:146,225,941...146,228,868
Ensembl chr 3:146,226,407...146,228,834
|
|
G |
Npnt |
nephronectin |
increases expression |
ISO |
Triiodothyronine results in increased expression of NPNT mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 2:221,391,151...221,459,527
Ensembl chr 2:221,391,153...221,459,401
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of NR0B2 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
Triiodothyronine binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:33049310 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]; Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA] |
CTD |
PMID:21726595 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nrgn |
neurogranin |
increases expression multiple interactions |
EXP |
Triiodothyronine results in increased expression of NRGN mRNA; Triiodothyronine results in increased expression of NRGN protein Triiodothyronine inhibits the reaction [Propylthiouracil results in decreased expression of and results in decreased phosphorylation of NRGN protein]; Triiodothyronine inhibits the reaction [Propylthiouracil results in decreased expression of NRGN mRNA] |
CTD |
PMID:15708448 PMID:29796989 |
|
NCBI chr 8:37,255,462...37,263,659
Ensembl chr 8:37,256,930...37,257,516
|
|
G |
Nrp1 |
neuropilin 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of NRP1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
increases expression |
EXP |
Triiodothyronine results in increased expression of NSDHL mRNA |
CTD |
PMID:15953391 |
|
NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142
|
|
G |
Nsmf |
NMDA receptor synaptonuclear signaling and neuronal migration factor |
increases expression |
EXP |
Triiodothyronine results in increased expression of NSMF mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 3:7,861,846...7,870,615
Ensembl chr 3:7,861,872...7,870,614
|
|
G |
Nt5e |
5' nucleotidase, ecto |
increases expression increases activity |
EXP |
Triiodothyronine results in increased expression of NT5E mRNA Triiodothyronine results in increased activity of NT5E protein |
CTD |
PMID:15543949 |
|
NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881
|
|
G |
Nudt7 |
nudix hydrolase 7 |
increases expression |
EXP |
Triiodothyronine results in increased expression of NUDT7 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr19:42,125,679...42,151,198
Ensembl chr19:42,125,711...42,151,081
|
|
G |
Nup214 |
nucleoporin 214 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of NUP214 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 3:15,255,111...15,340,568
Ensembl chr 3:15,255,119...15,340,568
|
|
G |
Ocln |
occludin |
increases expression |
EXP |
Triiodothyronine results in increased expression of OCLN mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Olig2 |
oligodendrocyte transcription factor 2 |
decreases expression |
EXP |
Triiodothyronine results in decreased expression of OLIG2 protein |
CTD |
PMID:25200619 |
|
NCBI chr11:30,475,510...30,478,886
Ensembl chr11:30,475,398...30,480,152
|
|
G |
Olr59 |
olfactory receptor 59 |
increases expression |
EXP |
Triiodothyronine results in increased expression of OLR59 mRNA |
CTD |
PMID:28299817 |
|
NCBI chr 1:157,193,051...157,227,707
Ensembl chr 1:157,193,080...157,211,179
|
|
G |
Osgin1 |
oxidative stress induced growth inhibitor 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of OSGIN1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr19:47,471,750...47,500,517
Ensembl chr19:47,492,171...47,500,516
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
multiple interactions affects binding |
EXP |
4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine binds to P4HB protein]; bisphenol A inhibits the reaction [Triiodothyronine binds to P4HB protein]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of and results in increased secretion of GH protein]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 protein]; Polychlorinated Biphenyls metabolite inhibits the reaction [Triiodothyronine binds to P4HB protein] |
CTD |
PMID:17928132 PMID:18515855 PMID:19374345 PMID:22201216 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Padi4 |
peptidyl arginine deiminase 4 |
increases expression |
EXP |
Triiodothyronine results in increased expression of PADI4 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 5:153,041,351...153,074,412
Ensembl chr 5:153,041,352...153,074,362
|
|
G |
Parp4 |
poly (ADP-ribose) polymerase family, member 4 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of PARP4 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr15:30,690,503...30,792,868
Ensembl chr15:30,686,613...30,828,810
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions increases expression |
EXP ISO |
SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PCK1 mRNA] (4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of PCK1 mRNA]; SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of PCK1 mRNA] |
CTD |
PMID:21815645 PMID:23209300 PMID:30209975 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pcna |
proliferating cell nuclear antigen |
affects binding multiple interactions increases expression |
ISO |
Triiodothyronine analog binds to PCNA protein; Triiodothyronine binds to PCNA protein Triiodothyronine analog inhibits the reaction [CDKN1A protein binds to PCNA protein]; Triiodothyronine analog inhibits the reaction [POLD3 protein binds to PCNA protein]; Triiodothyronine inhibits the reaction [CDKN1A protein binds to PCNA protein] THRB protein promotes the reaction [Triiodothyronine results in increased expression of PCNA protein] |
CTD |
PMID:20638743 PMID:22383522 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pcsk1 |
proprotein convertase subtilisin/kexin type 1 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of PCSK1 mRNA |
CTD |
PMID:15291740 |
|
NCBI chr 2:4,395,543...4,442,434
Ensembl chr 2:4,395,543...4,442,434
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of PCSK2 mRNA |
CTD |
PMID:15585599 |
|
NCBI chr 3:130,880,422...131,183,127
Ensembl chr 3:130,880,422...131,183,127
|
|
G |
Pdgfra |
platelet derived growth factor receptor alpha |
decreases expression |
EXP |
Triiodothyronine results in decreased expression of PDGFRA protein |
CTD |
PMID:25200619 |
|
NCBI chr14:33,005,838...33,054,347
Ensembl chr14:33,005,839...33,054,335
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
multiple interactions increases expression |
ISO EXP |
resveratrol promotes the reaction [Triiodothyronine results in increased expression of PDK4 mRNA] resveratrol promotes the reaction [Triiodothyronine results in increased expression of PDK4 mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PDK4 mRNA] |
CTD |
PMID:23209300 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pdp2 |
pyruvate dehydrogenase phosphatase catalytic subunit 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of PDP2 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr19:386,408...394,068
Ensembl chr19:386,406...394,074
|
|
G |
Peg10 |
paternally expressed 10 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PEG10 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 4:32,842,441...32,855,639
Ensembl chr 4:32,848,493...32,852,621
|
|
G |
Pex5 |
peroxisomal biogenesis factor 5 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PEX5 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 4:157,270,671...157,296,432
Ensembl chr 4:157,270,672...157,296,431
|
|
G |
Pfkp |
phosphofructokinase, platelet |
increases expression |
ISO |
Triiodothyronine results in increased expression of PFKP mRNA |
CTD |
PMID:15507505 |
|
NCBI chr17:63,729,743...63,794,026
Ensembl chr17:63,729,780...63,794,018
|
|
G |
Phospho1 |
phosphoethanolamine/phosphocholine phosphatase 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PHOSPHO1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr10:80,762,062...80,769,596
Ensembl chr10:80,760,792...80,770,342
|
|
G |
Pik3cd |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta |
increases expression |
ISO |
Triiodothyronine results in increased expression of PIK3CD mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930
|
|
G |
Pla2g6 |
phospholipase A2 group VI |
increases expression |
EXP |
Triiodothyronine results in increased expression of PLA2G6 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 7:110,851,378...110,891,557
Ensembl chr 7:110,851,378...110,891,114
|
|
G |
Pld5 |
phospholipase D family, member 5 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PLD5 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr13:87,895,694...88,232,868
Ensembl chr13:87,896,369...88,232,868
|
|
G |
Plin2 |
perilipin 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of PLIN2 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319
|
|
G |
Plin3 |
perilipin 3 |
multiple interactions |
ISO |
[THRA protein co-treated with Triiodothyronine] promotes the reaction [ANGPTL8 protein binds to PLIN3 protein] |
CTD |
PMID:24262987 |
|
NCBI chr 9:1,111,178...1,123,057
Ensembl chr 9:1,102,366...1,123,147
|
|
G |
Plxnc1 |
plexin C1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PLXNC1 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 7:29,390,038...29,543,985
Ensembl chr 7:29,390,048...29,543,779
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PMP22 mRNA |
CTD |
PMID:29901742 |
|
NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
increases expression decreases phosphorylation |
ISO |
Triiodothyronine results in increased expression of PNPLA2 mRNA Triiodothyronine results in decreased phosphorylation of PNPLA2 protein |
CTD |
PMID:30209975 |
|
NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805
|
|
G |
Podxl |
podocalyxin-like |
increases expression |
EXP |
Triiodothyronine results in increased expression of PODXL mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 4:60,135,124...60,181,829
Ensembl chr 4:60,135,109...60,181,899
|
|
G |
Pold3 |
DNA polymerase delta 3, accessory subunit |
multiple interactions |
ISO |
Triiodothyronine analog inhibits the reaction [POLD3 protein binds to PCNA protein] |
CTD |
PMID:22383522 |
|
NCBI chr 1:154,417,893...154,456,687
Ensembl chr 1:154,418,084...154,456,665
|
|
G |
Polg |
DNA polymerase gamma, catalytic subunit |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of POLG mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 1:133,382,764...133,399,578
Ensembl chr 1:133,382,766...133,398,567
|
|
G |
Pomt1 |
protein-O-mannosyltransferase 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of POMT1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 3:15,520,717...15,538,579
Ensembl chr 3:15,520,481...15,538,581
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of POU5F1 mRNA Chlorpyrifos inhibits the reaction [Triiodothyronine results in increased expression of POU5F1 mRNA]; Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of POU5F1 mRNA] |
CTD |
PMID:34571837 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP ISO |
[GW 7647 results in increased activity of PPARA protein] promotes the reaction [Phenobarbital results in increased degradation of Triiodothyronine]; [pirinixic acid results in increased activity of PPARA protein] promotes the reaction [Phenobarbital results in increased degradation of Triiodothyronine]; [Triiodothyronine co-treated with Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Triiodothyronine inhibits the reaction [Acetaminophen results in decreased expression of PPARA mRNA] |
CTD |
PMID:19631232 PMID:25048947 PMID:33476690 PMID:35662663 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions |
ISO |
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP ISO |
Triiodothyronine inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA] Triiodothyronine binds to and results in increased activity of PPARG protein [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Triiodothyronine binds to and results in increased activity of PPARG protein |
CTD |
PMID:25048947 PMID:33049310 PMID:33476690 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
EXP ISO |
Triiodothyronine results in increased expression of PPARGC1A mRNA [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:23209300 PMID:30209975 PMID:33091441 PMID:33476690 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prdm16 |
PR/SET domain 16 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of PRDM16 mRNA [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA |
CTD |
PMID:30209975 PMID:33091441 |
|
NCBI chr 5:164,879,864...165,203,986
Ensembl chr 5:164,880,587...165,203,601
|
|
G |
Prelp |
proline and arginine rich end leucine rich repeat protein |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of PRELP mRNA |
CTD |
PMID:25172293 |
|
NCBI chr13:45,368,407...45,391,480
Ensembl chr13:45,370,533...45,380,270
|
|
G |
Prickle2 |
prickle planar cell polarity protein 2 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of PRICKLE2 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 4:124,869,655...125,214,862
Ensembl chr 4:124,869,552...125,214,824
|
|
G |
Prl |
prolactin |
decreases expression multiple interactions increases secretion |
EXP |
Triiodothyronine results in decreased expression of PRL mRNA; Triiodothyronine results in decreased expression of PRL protein bisphenol A inhibits the reaction [Triiodothyronine results in increased secretion of PRL protein]; Chlorodiphenyl (54% Chlorine) promotes the reaction [Triiodothyronine results in increased secretion of PRL protein] |
CTD |
PMID:3734668 PMID:17615682 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Prokr1 |
prokineticin receptor 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PROKR1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 4:120,022,301...120,033,367
Ensembl chr 4:120,021,747...120,033,379
|
|
G |
Psca |
prostate stem cell antigen |
multiple interactions increases expression |
ISO |
4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of PSCA mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of PSCA mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of PSCA mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of PSCA protein] Triiodothyronine results in increased expression of PSCA mRNA; Triiodothyronine results in increased expression of PSCA protein |
CTD |
PMID:14761676 |
|
NCBI chr 7:106,598,203...106,603,114
Ensembl chr 7:106,595,284...106,609,746
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PTGS2 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rab23 |
RAB23, member RAS oncogene family |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of RAB23 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 9:35,943,522...35,967,367
Ensembl chr 9:35,944,085...35,966,927
|
|
G |
Rab3b |
RAB3B, member RAS oncogene family |
increases expression |
ISO |
Triiodothyronine results in increased expression of RAB3B mRNA |
CTD |
PMID:15507505 |
|
NCBI chr 5:123,629,562...123,697,410
Ensembl chr 5:123,644,423...123,697,401
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
multiple interactions |
ISO |
RAP1A protein promotes the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of Triiodothyronine] |
CTD |
PMID:38522500 |
|
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Rarb |
retinoic acid receptor, beta |
increases expression |
EXP |
Triiodothyronine results in increased expression of RARB mRNA |
CTD |
PMID:15708448 |
|
NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases activity |
EXP |
Hexachlorocyclohexane affects the reaction [Triiodothyronine results in increased activity of RELA protein] |
CTD |
PMID:15019085 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Retsat |
retinol saturase |
increases expression |
EXP |
Triiodothyronine results in increased expression of RETSAT mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 4:104,653,306...104,662,069
Ensembl chr 4:104,653,155...104,668,310
|
|
G |
Rhov |
ras homolog family member V |
increases expression |
ISO |
Triiodothyronine results in increased expression of RHOV mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 3:106,260,774...106,270,009
Ensembl chr 3:106,260,776...106,269,479
|
|
G |
Rpa2 |
replication protein A2 |
increases phosphorylation |
ISO |
Triiodothyronine analog results in increased phosphorylation of RPA2 protein |
CTD |
PMID:22383522 |
|
NCBI chr 5:144,976,789...144,989,445
Ensembl chr 5:144,976,748...144,987,350
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions decreases phosphorylation |
ISO |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Triiodothyronine results in decreased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:30209975 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rxrb |
retinoid X receptor beta |
increases expression |
EXP |
Triiodothyronine results in increased expression of RXRB mRNA |
CTD |
PMID:15708448 |
|
NCBI chr20:4,816,813...4,823,267
Ensembl chr20:4,816,815...4,828,773
|
|
G |
Rxrg |
retinoid X receptor gamma |
increases expression |
EXP |
Triiodothyronine results in increased expression of RXRG mRNA |
CTD |
PMID:15708448 |
|
NCBI chr13:79,743,430...79,785,173
Ensembl chr13:79,743,563...79,785,167
|
|
G |
S100a6 |
S100 calcium binding protein A6 |
multiple interactions |
EXP |
S100A6 protein inhibits the reaction [Triiodothyronine results in increased expression of MYH6 mRNA] |
CTD |
PMID:15652358 |
|
NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180
|
|
G |
Sc5d |
sterol-C5-desaturase |
increases expression |
EXP |
Triiodothyronine results in increased expression of SC5D mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 8:42,629,649...42,641,257
Ensembl chr 8:42,632,672...42,641,273
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
EXP |
Triiodothyronine results in increased expression of SCD1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Serpina6 |
serpin family A member 6 |
increases expression |
EXP |
Triiodothyronine results in increased expression of SERPINA6 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 6:122,780,040...122,790,274
Ensembl chr 6:122,780,043...122,790,349
|
|
G |
Serpina7 |
serpin family A member 7 |
affects binding |
ISO |
Triiodothyronine binds to SERPINA7 protein |
CTD |
PMID:20804816 PMID:21517007 |
|
NCBI chr X:102,663,242...102,722,319
Ensembl chr X:102,663,405...102,669,040
|
|
G |
Sigmar1 |
sigma non-opioid intracellular receptor 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of SIGMAR1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 5:56,904,155...56,907,012
Ensembl chr 5:56,904,159...56,907,017
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions affects response to substance increases expression |
EXP |
SIRT1 protein affects the reaction [Triiodothyronine results in decreased activity of SREBF1 protein]; SIRT1 protein affects the reaction [Triiodothyronine results in decreased expression of SREBF1 mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A protein]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PCK1 mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PDK4 mRNA] SIRT1 protein affects the susceptibility to Triiodothyronine Triiodothyronine results in increased expression of SIRT1 mRNA |
CTD |
PMID:23209300 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc10a2 |
solute carrier family 10 member 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of SLC10A2 mRNA |
CTD |
PMID:28299817 |
|
NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
|
|
G |
Slc15a1 |
solute carrier family 15 member 1 |
multiple interactions decreases expression |
ISO |
resveratrol inhibits the reaction [Triiodothyronine results in decreased expression of SLC15A1 mRNA]; resveratrol inhibits the reaction [Triiodothyronine results in decreased expression of SLC15A1 protein] Triiodothyronine results in decreased expression of SLC15A1 mRNA; Triiodothyronine results in decreased expression of SLC15A1 protein |
CTD |
PMID:26394120 |
|
NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545
|
|
G |
Slc16a2 |
solute carrier family 16 member 2 |
multiple interactions increases uptake |
ISO |
bisphenol A inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; bosutinib inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Dasatinib inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Desipramine inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Genistein inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Imatinib Mesylate inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Indocyanine Green inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Meclofenamic Acid inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Phloretin inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Sulfobromophthalein inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine] |
CTD |
PMID:28119167 |
|
NCBI chr X:68,725,365...68,848,572
Ensembl chr X:68,723,261...68,848,771
|
|
G |
Slc16a3 |
solute carrier family 16 member 3 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SLC16A3 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr10:106,212,679...106,222,564
Ensembl chr10:106,212,778...106,222,562
|
|
G |
Slc16a6 |
solute carrier family 16, member 6 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of SLC16A6 mRNA (4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of SLC16A6 mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr10:94,424,377...94,447,482
Ensembl chr10:94,426,244...94,448,779
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SLC1A2 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498
|
|
G |
Slc25a25 |
solute carrier family 25 member 25 |
increases expression |
EXP |
Triiodothyronine results in increased expression of SLC25A25 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 3:15,708,702...15,742,195
Ensembl chr 3:15,708,703...15,742,216
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SLC2A1 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 protein |
CTD |
PMID:27605626 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc2a5 |
solute carrier family 2 member 5 |
multiple interactions |
EXP |
[Triiodothyronine co-treated with Fructose] results in increased expression of SLC2A5 mRNA |
CTD |
PMID:17485832 |
|
NCBI chr 5:160,583,055...160,609,994
Ensembl chr 5:160,583,234...160,611,106
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of SLC38A2 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 7:127,851,267...127,863,482
Ensembl chr 7:127,851,267...127,863,436
|
|
G |
Slc43a2 |
solute carrier family 43 member 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SLC43A2 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr10:60,375,462...60,420,838
Ensembl chr10:60,376,559...60,418,244
|
|
G |
Slc51b |
SLC51 subunit beta |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of SLC51B mRNA (4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of SLC51B mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SLC7A11 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
Triiodothyronine results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Sned1 |
sushi, nidogen and EGF-like domains 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SNED1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 9:93,774,087...93,834,003
Ensembl chr 9:93,774,119...93,830,694
|
|
G |
Snora28 |
small nucleolar RNA, H/ACA box 28 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of SNORA28 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 6:130,591,965...130,592,090
Ensembl chr 6:130,591,965...130,592,090
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions decreases expression |
ISO |
Triiodothyronine inhibits the reaction [Paraquat results in decreased expression of SOD1 mRNA]; Triiodothyronine inhibits the reaction [THRA protein results in increased expression of SOD1 mRNA]; Triiodothyronine inhibits the reaction [THRB protein results in increased expression of SOD1 mRNA] Triiodothyronine results in decreased expression of SOD1 mRNA |
CTD |
PMID:16738222 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sox10 |
SRY-box transcription factor 10 |
multiple interactions |
ISO |
[pyriproxyfen metabolite co-treated with Triiodothyronine] results in decreased expression of SOX10 mRNA |
CTD |
PMID:34289950 |
|
NCBI chr 7:110,725,274...110,734,651
Ensembl chr 7:110,725,274...110,735,544
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
multiple interactions decreases expression |
ISO |
[Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of SOX9 mRNA Triiodothyronine results in decreased expression of SOX9 mRNA |
CTD |
PMID:34571837 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Spen |
spen family transcriptional repressor |
increases expression |
ISO |
Triiodothyronine results in increased expression of SPEN mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 5:153,775,287...153,848,677
Ensembl chr 5:153,776,234...153,848,811
|
|
G |
Sptlc2 |
serine palmitoyltransferase, long chain base subunit 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SPTLC2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 6:106,948,682...107,031,532
Ensembl chr 6:106,950,949...107,031,542
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions increases expression |
ISO |
[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein; Ammonium Chloride inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; ANGPTL8 protein affects the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein] Triiodothyronine results in increased expression of SQSTM1 mRNA |
CTD |
PMID:24262987 PMID:30209975 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]] |
CTD |
PMID:22227104 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions decreases activity decreases expression |
EXP ISO |
SIRT1 protein affects the reaction [Triiodothyronine results in decreased activity of SREBF1 protein]; SIRT1 protein affects the reaction [Triiodothyronine results in decreased expression of SREBF1 mRNA] [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA] |
CTD |
PMID:23209300 PMID:33476690 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srsf3 |
serine and arginine rich splicing factor 3 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of SFRS3 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr20:7,091,928...7,101,860
Ensembl chr20:7,091,910...7,101,078
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]]; [Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of STAR mRNA; Triiodothyronine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA] |
CTD |
PMID:21726595 PMID:34571837 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stard8 |
StAR-related lipid transfer domain containing 8 |
increases expression |
ISO |
Triiodothyronine results in increased expression of STARD8 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr X:64,079,079...64,196,052
Ensembl chr X:64,124,574...64,196,052
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
Triiodothyronine inhibits the reaction [FGF2 protein results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:16150908 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat5a |
signal transducer and activator of transcription 5A |
increases expression |
ISO |
Triiodothyronine results in increased expression of STAT5A mRNA |
CTD |
PMID:25172293 |
|
NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866
|
|
G |
Stat5b |
signal transducer and activator of transcription 5B |
increases expression |
EXP |
Triiodothyronine results in increased expression of STAT5B mRNA |
CTD |
PMID:15953391 |
|
NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668
|
|
G |
Stk19 |
serine/threonine kinase 19 |
increases expression |
ISO |
Triiodothyronine results in increased expression of STK19 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr20:3,995,590...4,005,117
Ensembl chr20:3,995,587...4,005,116
|
|
G |
Stra8 |
stimulated by retinoic acid 8 |
decreases expression multiple interactions |
ISO |
Triiodothyronine results in decreased expression of STRA8 mRNA [Chlorpyrifos co-treated with Triiodothyronine] results in decreased expression of STRA8 mRNA; [Ethylenethiourea co-treated with Triiodothyronine] results in decreased expression of STRA8 mRNA |
CTD |
PMID:34571837 |
|
NCBI chr 4:63,601,443...63,624,777
Ensembl chr 4:63,601,604...63,624,771
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
increases sulfation affects sulfation multiple interactions |
ISO |
SULT1A1 protein results in increased sulfation of Triiodothyronine SULT1A1 gene polymorphism affects the sulfation of Triiodothyronine Triiodothyronine inhibits the reaction [SULT1A1 protein results in increased sulfation of 4-nitrophenol] |
CTD |
PMID:11739018 PMID:15531517 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of SULT2A1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
|
|
G |
Sult4a1 |
sulfotransferase family 4A, member 1 |
increases metabolic processing |
ISO |
SULT4A1 protein results in increased metabolism of Triiodothyronine |
CTD |
PMID:12039030 |
|
NCBI chr 7:115,216,066...115,240,156
Ensembl chr 7:115,216,066...115,240,085
|
|
G |
Sycp1 |
synaptonemal complex protein 1 |
decreases expression multiple interactions |
ISO |
Triiodothyronine results in decreased expression of SYCP1 mRNA [Chlorpyrifos co-treated with Triiodothyronine] results in decreased expression of SYCP1 mRNA; [Ethylenethiourea co-treated with Triiodothyronine] results in decreased expression of SYCP1 mRNA |
CTD |
PMID:34571837 |
|
NCBI chr 2:190,296,688...190,456,687
Ensembl chr 2:190,296,954...190,456,737
|
|
G |
Taf5l1 |
TATA-box binding protein associated factor 5 like 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of TAF5L mRNA |
CTD |
PMID:23397585 |
|
NCBI chr19:51,991,704...52,011,001
Ensembl chr19:51,991,708...52,011,295
|
|
G |
Tcim |
transcriptional and immune response regulator |
multiple interactions increases expression |
ISO |
SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of TCIM mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr16:67,595,762...67,597,055
Ensembl chr16:67,593,410...67,597,581
|
|
G |
Tex264 |
testis expressed 264 |
increases expression |
EXP |
Triiodothyronine results in increased expression of TEX264 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 8:107,295,806...107,322,858
Ensembl chr 8:107,295,806...107,323,232
|
|
G |
Tf |
transferrin |
multiple interactions |
ISO |
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511
|
|
G |
Tfeb |
transcription factor EB |
increases expression |
ISO |
Triiodothyronine results in increased expression of TFEB mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 9:13,198,890...13,254,726
Ensembl chr 9:13,198,891...13,254,714
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP ISO |
Triiodothyronine inhibits the reaction [TGFB1 protein results in increased secretion of MMP2 protein]; Triiodothyronine promotes the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA |
CTD |
PMID:18031379 PMID:33476690 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgoln2 |
trans-golgi network protein 2 |
decreases expression increases expression |
ISO |
Triiodothyronine results in decreased expression of TGOLN2 mRNA Triiodothyronine results in increased expression of TGOLN2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 4:104,663,356...104,671,208
Ensembl chr 4:104,663,353...104,671,164
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions increases expression decreases expression increases activity affects binding |
ISO EXP |
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of THRA mRNA]; 2,2',4,4'-tetrabromodiphenyl ether analog affects the reaction [Triiodothyronine binds to THRA protein]; 4,4'-bisphenol F inhibits the reaction [Triiodothyronine binds to THRA protein]; [THRA protein co-treated with Triiodothyronine] promotes the reaction [ANGPTL8 protein binds to PLIN3 protein]; [THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 protein; Ammonium Chloride inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; ANGPTL8 protein affects the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; bisphenol A inhibits the reaction [Triiodothyronine binds to THRA protein]; bisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; bisphenol S inhibits the reaction [Triiodothyronine binds to THRA protein]; Chloroquine inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; daidzein promotes the reaction [Triiodothyronine results in increased activity of THRA protein]; Genistein promotes the reaction [Triiodothyronine results in increased activity of THRA protein]; KB 130015 inhibits the reaction [Triiodothyronine binds to and results in increased activity of THRA protein]; pentabromodiphenyl ether analog inhibits the reaction [Triiodothyronine binds to THRA protein]; Polybrominated Biphenyls metabolite inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine binds to THRA protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; tetrachlorodian inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased cleavage of CASP3 protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CASP3 mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CYCS mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL1B mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL6 mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of TNF mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL1B protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL6 protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of TNF protein]]; tribromodiphenyl ether 28 analog affects the reaction [Triiodothyronine binds to THRA protein]; Triiodothyronine binds to and results in increased activity of THRA protein; Triiodothyronine inhibits the reaction [THRA protein results in increased expression of SOD1 mRNA]; Triiodothyronine promotes the reaction [NCOA2 protein binds to THRA protein]; Triiodothyronine promotes the reaction [THRA protein binds to NCOA2 protein] Triiodothyronine results in increased expression of THRA mRNA; Triiodothyronine results in increased expression of THRA protein Triiodothyronine results in decreased expression of THRA mRNA [bisphenol A co-treated with Estradiol co-treated with Triiodothyronine] results in increased expression of THRA mRNA; [bisphenol A co-treated with Triiodothyronine] results in increased expression of THRA mRNA; Polybrominated Biphenyls inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; Polybrominated Biphenyls metabolite inhibits the reaction [Triiodothyronine binds to THRA protein]; THRA protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; Triiodothyronine binds to and results in increased activity of THRA protein; Triiodothyronine inhibits the reaction [Propylthiouracil results in decreased expression of THRA mRNA] 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine results in increased expression of THRA mRNA]; [Triiodothyronine co-treated with Chlorpyrifos] results in decreased expression of THRA mRNA; [Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of THRA mRNA; CSK protein promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine binds to THRA protein]]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine binds to THRA protein]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]; Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA] |
CTD |
PMID:7684602 PMID:9664232 PMID:11806713 PMID:12109914 PMID:12414890 PMID:12588052 PMID:15680168 PMID:15708448 PMID:16021636 PMID:16023420 PMID:16738222 PMID:19672399 PMID:21396401 PMID:21726595 PMID:22015988 PMID:22086976 PMID:23112079 PMID:23402801 PMID:24076165 PMID:24262987 PMID:24819616 PMID:25646720 PMID:27993100 PMID:28167136 PMID:29146198 PMID:29688519 PMID:29796989 PMID:31566444 PMID:32223187 PMID:33049310 PMID:33095664 PMID:34571837 More...
|
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions increases expression affects binding increases activity increases response to substance decreases expression |
ISO EXP |
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; 2,2',4,4'-tetrabromodiphenyl ether analog affects the reaction [Triiodothyronine binds to THRB protein]; 2,2',4,4'-tetrabromodiphenyl ether metabolite inhibits the reaction [Triiodothyronine binds to THRB protein]; 2,3,4,7,8-pentachlorodibenzofuran inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; 2,4,6-tribromophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; 2,4,6-trichlorophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; 2,4,6-triiodophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; 4,4'-bisphenol F inhibits the reaction [Triiodothyronine binds to THRB protein]; 4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Triiodothyronine binds to THRB protein]; 4-nonylphenol inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; 4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; 6-OH-BDE-47 inhibits the reaction [Triiodothyronine binds to THRB protein]; [THRB protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; [Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Amiodarone inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; bisphenol A analog inhibits the reaction [Triiodothyronine binds to THRB protein]; bisphenol A inhibits the reaction [[Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein]; bisphenol A inhibits the reaction [Triiodothyronine binds to THRB protein]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; bisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; bisphenol S analog inhibits the reaction [Triiodothyronine binds to THRB protein]; bisphenol S analog inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; bisphenol S inhibits the reaction [Triiodothyronine binds to THRB protein]; bisphenol S inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; cyhalothrin inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; daidzein promotes the reaction [Triiodothyronine results in increased activity of THRB protein]; deoxynivalenol inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; desethylamiodarone inhibits the reaction [Triiodothyronine binds to THRB protein alternative form]; Genistein promotes the reaction [Triiodothyronine results in increased activity of THRB protein]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; KB 130015 inhibits the reaction [Triiodothyronine binds to and results in increased activity of THRB protein]; methoxyacetic acid promotes the reaction [Triiodothyronine results in increased activity of THRB protein]; pentabromodiphenyl ether analog inhibits the reaction [Triiodothyronine binds to THRB protein]; pentabromophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; Polybrominated Biphenyls metabolite inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; systhane inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; T-2 Toxin inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine binds to THRB protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tetrachlorodian analog inhibits the reaction [Triiodothyronine binds to THRB protein]; tetrachlorodian inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Thyroxine inhibits the reaction [Triiodothyronine binds to THRB protein]; Tretinoin inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tribromodiphenyl ether 28 analog affects the reaction [Triiodothyronine binds to THRB protein]; Triclosan inhibits the reaction [Triiodothyronine binds to THRB protein]; Triiodothyronine binds to and results in increased activity of THRB protein; Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]; Triiodothyronine inhibits the reaction [THRB protein results in increased expression of SOD1 mRNA]; Triiodothyronine promotes the reaction [NCOA2 protein binds to THRB protein]; Triiodothyronine promotes the reaction [THRB protein binds to NCOA2 protein]; Zearalenone inhibits the reaction [Triiodothyronine results in increased activity of THRB protein] Triiodothyronine results in increased expression of THRB mRNA; Triiodothyronine results in increased expression of THRB protein [bisphenol A co-treated with Estradiol co-treated with Triiodothyronine] results in increased expression of THRB mRNA; [bisphenol A co-treated with Triiodothyronine] results in increased expression of THRB mRNA; Butyric Acid inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; desethylamiodarone inhibits the reaction [Triiodothyronine binds to THRB protein]; Polybrominated Biphenyls inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; THRB protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; THRB protein promotes the reaction [Triiodothyronine results in increased expression of ATP2A2 mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of THRB mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of THRB protein] Chlorpyrifos inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; THRB protein promotes the reaction [Triiodothyronine results in decreased expression of CDKN1B protein]; THRB protein promotes the reaction [Triiodothyronine results in increased expression of CCND1 protein]; THRB protein promotes the reaction [Triiodothyronine results in increased expression of PCNA protein] THRB protein results in increased susceptibility to Triiodothyronine Triiodothyronine results in decreased expression of THRB mRNA |
CTD |
PMID:2211641 PMID:8137729 PMID:11577024 PMID:11806713 PMID:12109914 PMID:12414890 PMID:12538616 PMID:12588052 PMID:15103026 PMID:15598685 PMID:15680168 PMID:15708448 PMID:16021636 PMID:16738222 PMID:18486176 PMID:18584933 PMID:18795168 PMID:19457453 PMID:19672399 PMID:20638743 PMID:20737425 PMID:21396401 PMID:22015988 PMID:22227104 PMID:23112079 PMID:23402801 PMID:24262987 PMID:25646720 PMID:27410513 PMID:27420076 PMID:27993100 PMID:28167136 PMID:28531659 PMID:28973306 PMID:29146198 PMID:29409039 PMID:29688519 PMID:29763311 PMID:31077750 PMID:31476497 PMID:31566444 PMID:33049310 PMID:33095664 PMID:34571837 More...
|
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Thrsp |
thyroid hormone responsive |
multiple interactions increases expression |
EXP ISO |
Triiodothyronine inhibits the reaction [Amiodarone results in increased expression of THRSP mRNA] Triiodothyronine results in increased expression of THRSP mRNA [Chlorpyrifos co-treated with Triiodothyronine] results in increased expression of THRSP mRNA; [Ethylenethiourea co-treated with Triiodothyronine] results in increased expression of THRSP mRNA |
CTD |
PMID:2721112 PMID:10357836 PMID:15953391 PMID:28478156 PMID:34571837 |
|
NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075
|
|
G |
Tmem184b |
transmembrane protein 184B |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of TMEM184B mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 7:110,925,092...110,967,975
Ensembl chr 7:110,925,092...110,967,943
|
|
G |
Tmem44 |
transmembrane protein 44 |
increases expression |
ISO |
Triiodothyronine results in increased expression of TMEM44 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr11:70,181,120...70,216,958
Ensembl chr11:70,181,345...70,216,958
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
[Triiodothyronine co-treated with Hexachlorocyclohexane] results in increased expression of TNF mRNA; [Triiodothyronine co-treated with Hexachlorocyclohexane] results in increased expression of TNF protein; Hexachlorocyclohexane inhibits the reaction [Triiodothyronine results in increased expression of TNF protein]; Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of TNF protein]; Triiodothyronine inhibits the reaction [Propylthiouracil results in increased expression of TNF mRNA] THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of TNF mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of TNF protein]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of TNF mRNA]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of TNF protein] |
CTD |
PMID:15019085 PMID:29796989 PMID:32223187 PMID:36868496 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf9 |
TNF receptor superfamily member 9 |
multiple interactions increases expression |
ISO |
4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of TNFRSF9 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of TNFRSF9 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TNFRSF9 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TNFRSF9 protein] Triiodothyronine results in increased expression of TNFRSF9 mRNA; Triiodothyronine results in increased expression of TNFRSF9 protein |
CTD |
PMID:14761676 |
|
NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000
|
|
G |
Tomm20 |
translocase of outer mitochondrial membrane 20 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of TOMM20 protein Chloroquine promotes the reaction [Triiodothyronine results in increased expression of TOMM20 protein]; Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of TOMM20 protein] |
CTD |
PMID:30209975 |
|
NCBI chr19:54,925,197...54,935,188
Ensembl chr19:54,923,402...54,935,198
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
multiple interactions increases expression |
ISO |
4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of TRAF1 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of TRAF1 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TRAF1 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TRAF1 protein] Triiodothyronine results in increased expression of TRAF1 mRNA; Triiodothyronine results in increased expression of TRAF1 protein |
CTD |
PMID:14761676 |
|
NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807
|
|
G |
Trim46 |
tripartite motif-containing 46 |
increases expression |
ISO |
Triiodothyronine results in increased expression of TRIM46 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 2:174,641,494...174,654,237
Ensembl chr 2:174,641,496...174,654,141
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
decreases expression increases secretion multiple interactions |
ISO EXP |
Triiodothyronine results in decreased expression of TSHB mRNA TSHB protein results in increased secretion of Triiodothyronine [Triiodothyronine co-treated with 2,2',4,4'-tetrabromodiphenyl ether] results in decreased expression of TSHB mRNA alternative form |
CTD |
PMID:7827627 PMID:9092800 PMID:11288978 PMID:27420076 PMID:28167136 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Ttbk1 |
tau tubulin kinase 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of TTBK1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 9:14,493,166...14,538,372
Ensembl chr 9:14,493,389...14,535,774
|
|
G |
Ttn |
titin |
multiple interactions affects expression |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine affects the expression of TTN mRNA]; AKT1 protein affects the reaction [Triiodothyronine affects the expression of TTN mRNA] |
CTD |
PMID:18096819 |
|
NCBI chr 3:61,652,432...61,924,912
Ensembl chr 3:61,652,439...61,924,741
|
|
G |
Ttr |
transthyretin |
affects binding |
ISO |
Triiodothyronine binds to TTR protein |
CTD |
PMID:20804816 PMID:21517007 |
|
NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008
|
|
G |
Ucp1 |
uncoupling protein 1 |
multiple interactions increases expression |
ISO EXP |
(+)-JQ1 compound inhibits the reaction [[Triiodothyronine co-treated with Rosiglitazone co-treated with INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of UCP1 mRNA]; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein; [Triiodothyronine co-treated with Rosiglitazone co-treated with INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of UCP1 mRNA [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [Triiodothyronine co-treated with Norepinephrine] results in increased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]; Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]; Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA] Triiodothyronine results in increased expression of UCP1 mRNA; Triiodothyronine results in increased expression of UCP1 protein [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA] |
CTD |
PMID:11742803 PMID:26972250 PMID:30209975 PMID:33091441 PMID:33476690 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
EXP |
THRA protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; THRB protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 mRNA]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 protein]; Triiodothyronine promotes the reaction [Bezafibrate results in increased expression of UCP2 mRNA]; Triiodothyronine promotes the reaction [carboprostacyclin results in increased expression of UCP2 mRNA]; Triiodothyronine promotes the reaction [darglitazone results in increased expression of UCP2 mRNA] |
CTD |
PMID:12588052 PMID:25048947 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Ugcg |
UDP-glucose ceramide glucosyltransferase |
increases activity |
EXP |
Triiodothyronine results in increased activity of UGCG protein |
CTD |
PMID:9101438 |
|
NCBI chr 5:74,032,978...74,065,701
Ensembl chr 5:74,032,978...74,065,393
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
decreases expression multiple interactions |
EXP |
Triiodothyronine results in decreased expression of UGT1A1 mRNA Vitamin A inhibits the reaction [Triiodothyronine results in decreased expression of UGT1A1 mRNA] |
CTD |
PMID:11299074 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
increases expression multiple interactions |
EXP |
Triiodothyronine results in increased expression of UGT1A6 mRNA Vitamin A inhibits the reaction [Triiodothyronine results in increased expression of UGT1A6 mRNA] |
CTD |
PMID:11299074 |
|
NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Utp20 |
UTP20 small subunit processome component |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of UTP20 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 7:23,134,630...23,215,639
Ensembl chr 7:23,134,637...23,215,632
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of VDAC1 protein Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of VDAC1 protein] |
CTD |
PMID:30209975 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA |
CTD |
PMID:33091441 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Wls |
Wnt ligand secretion mediator |
increases expression |
ISO |
Triiodothyronine results in increased expression of WLS mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 2:248,931,885...249,047,248
Ensembl chr 2:248,931,903...249,048,298
|
|
G |
Wnt4 |
Wnt family member 4 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Chlorpyrifos] results in decreased expression of WNT4 mRNA; [Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of WNT4 mRNA |
CTD |
PMID:34571837 |
|
NCBI chr 5:149,513,573...149,535,415
Ensembl chr 5:149,514,018...149,532,859
|
|
G |
Zc3h7b |
zinc finger CCCH-type containing 7B |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of ZC3H7B mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 7:113,262,142...113,310,399
Ensembl chr 7:113,262,165...113,310,399
|
|
G |
Zfp113 |
zinc finger protein 3 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of ZNF3 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr12:17,022,104...17,033,776
Ensembl chr12:17,022,279...17,033,709
|
|
G |
Zfp664 |
zinc finger protein 664 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ZNF664 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr12:31,767,792...31,796,038
Ensembl chr12:31,767,720...31,796,545
|
|
G |
Zmiz1 |
zinc finger, MIZ-type containing 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ZMIZ1 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr16:1,027,083...1,232,616
Ensembl chr16:1,027,325...1,232,597
|
|